摘要
目的探索一种疗效显著的新型肝癌介入治疗新药，对蓖麻毒蛋白糖脂脂质体包封物进行有关实验研究。方法以中药蓖麻子的提取物——蓖麻毒蛋白（ｒｉｃｉｎ，简称Ｒ）与糖脂脂质体—半乳糖神经酰胺（ｇａｌａｃｔｏｓｙｌｃｅｒａｍｉｄｅｌｉｐｏｓｏｍｅｓ，简称ＧＣＬ）进行包封后形成的蓖麻毒蛋白糖脂脂质体包封物（Ｒ－ＧＣＬ）作为设计药物进行实验研究，了解包封后的蓖麻毒蛋白对肝癌细胞的杀伤力。结果在体外实验中，当Ｒ为０．０５５μｇ／ｍｌ时，游离蓖麻毒蛋白作用后肝癌细胞的存活率为３８．５％，Ｒ－ＧＣＬ为２８．５％；当Ｒ为０．００５５μｇ／ｍｌ时，游离蓖麻毒蛋白作用后肝癌细胞的存活率为６４．７％，而Ｒ－ＧＣＬ为４６．６％。结论蓖麻毒蛋白糖脂脂质体包封物在体外实验中对肝细胞的杀伤作用明显强于游离蓖麻毒蛋白。
Objective To test the cytotoxicity and some characteristics of R GCL,a new encapsulated drug,to cultured human hepatoma cells.Methods Ricin was extracted and encapsulated with galactosyl ceramide.Human hepatoma cell line 7721 was cultured for testing its survival rate.Results The results of the cytotoxicity test showed that when the concentration of ricin was 0.055 μg/ml,the hepatoma cell survival rate of the free ricin was 38.5%, but 28.5%,of the entrapped one.When the concentration of ricin was 0.0055 μg/ml, the survival rate of the free ricin was 64.7%, and 46.6% of R GCL.Conclusion In vitro,the cytotoxicity of ricin containing galactosyl ceramide liposomes is much higher than that of free ricin.
基金
上海市卫生局课题
关键词
蓖麻毒蛋白
肝肿瘤
介入疗法
糖脂脂质体
ricin
galactosyl ceramide liposomes
encapsulation
cytotoxicity
hepatoma cells
